Literature DB >> 7938

Biochemical classification of herpes simplex virus types 1 and 2, and of intermediate strains on the basis of different susceptibilities of thymidine kinase to thymidine analogues.

I Just, S Dundaroff, D Falke.   

Abstract

Herpes simplex virus (HSV) type 1 can be differentiated from HSV type 2 on the basis of the sensitivity to 2'-deoxythymidine-5'-monophosphate of thymidine kinase induced in primary rabbit kidney cells. Whereas thymidine kinase induced by five strains of HSV type 1 (TK 1) is stimulated by suitable concentrations of 2'-deoxythymidine-5'-monophosphate, thymidine kinase induced by eight strains of HSV type 2 (TK 2) is inhibited. On the other hand, TK 2 is strongly inhibited by 2'-deoxythymidine-5'-triphosphate and by 2-bromo-2'-deoxyuridine-5'-triphosphate. The investigation of TK induced by six freshly isolated strains of HSV cross-reacting in neutralisation tests revealed two strains which induced TK 1 and two strains which induced TK 2. Two other strains induced thymidine kinase, the activity of which under the influence of these thymidine analogues was between that of TK 1 and TK 2. The properties of thymidine kinase remained constant after cloning the virus and thus is a genetically fixed trait due to recombination which could well occur in vivo.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 7938

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  3 in total

1.  Induction capacity and influence of dThdMP on thymidine kinase activity of type 1 and 2 strains of herpes simplex virus.

Authors:  S Dundarov; D Dundarova; S Todorov; L Kavaklova; D Falke
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

2.  The effect of dextransulfate 500 on the pathogenesis of herpes simplex virus infections in weanling mice.

Authors:  U Frank; L Caspary; H Hahn; D Falke
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

3.  Characterization of herpes simplex virus strains isolated from patients with various diseases.

Authors:  S Dundarov; P Andonov; B Bakalov
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.